查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362916

體外大腸直腸癌篩檢測試市場規模、佔有率、趨勢分析報告：按測試類型、地區和細分市場預測，2023-2030 年

In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test Type (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 129 Pages | 商品交期: 2-10個工作天內

價格

體外大腸直腸癌篩檢測試市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，2023年至2030年，全球體外大腸癌篩檢測試市場規模將以3.02%的年複合成長率擴張，預計2030年將達到11.2億美元。

為因應大腸直腸惡性不斷成長的趨勢而增加的新型篩檢模式是影響市場成長的主要要素。新開發的基因和生物標記測試的出現，如腫瘤 M2-PK糞便檢驗和甲基化基因測試，預計將提高腫瘤診斷模型的採用率。

惡性惡性腫瘤罹患率的增加是該領域成長的重要促進因素。例如，根據美國國家癌症中心2022年6月發布的資料，預計2022年日本將新增約1,019,000例癌症病例，其中估計新增158,200例大腸直腸癌（CRC）新病例。同樣，根據澳洲癌症協會 2022 年 8 月更新的資料，預計 2022 年澳洲將診斷出 15,713 例新的結直腸癌病例，其中男性診斷為 8,300 例，女性診斷為 7,413 例。因此，惡性惡性腫瘤患病的增加預計將推動對內視鏡設備的需求。

公共當局實施的各種促進篩檢的措施對體外結直腸癌篩檢的需求產生了積極影響。例如，Cancer.org 報導稱，即使在 COVID-19大流行開始之際，加州醫療保健提供者在 2020 年 4 月和 5 月期間仍繼續提供 FIT 試劑盒（糞便免疫化學檢查）。儘管如此，FIT反應率仍然很高。此外，歐洲癌症界已調動資源來評估、解決和減輕 COVID-19 對篩檢的負面影響。這些努力有助於滿足對體外篩選測試的持續需求。

此外，市場成長預計將受到主要市場參與企業增加產品推出的推動。這些產品的發布旨在提供技術先進和創新的產品。例如，Pillar Biosciences, Inc. 於 2021 年 7 月獲得 FDA核准用於 CRC 檢測的 ONCO/Reveal Dx 肺癌和結腸癌檢測 (O/RDx-LCCA)。

體外大腸直腸癌篩檢測試市場報告亮點：

  • 依檢測類型分類，2022年大便潛血試驗領域佔市場最大佔有率。
  • 在FOB檢測領域中，免疫FOB ELISA檢測在2022年佔據很大佔有率。這是因為免疫測試比傳統的癒創木脂 FOB糞便檢驗更準確。
  • 由於非侵入性篩檢方法的出現，預計生物標記測試在預測期內的收益佔有率將增加。
  • 與最近推出的產品（例如 ScheBo Biotech AG 的 ScheBo Oncology M2-PK糞便檢驗）相比，Oncology M2-PK糞便檢驗在 2022 年創造了最高的收益。
  • 在CRC DNA篩檢測試中，面板DNA測試（一種先進的基因篩檢測試）正在興起，並貢獻了最大的收益佔有率。
  • 北美在 2022 年佔據最大市場佔有率，這歸因於這些產品在黑色素瘤檢測臨床工作流程中的高採用率。
  • 市場上營運的主要企業包括 Abbott Laboratories、Quest Diagnostics、Siemens AG、Randox Laboratories、Kyowa Medex、GeneNews 等，以獲得更高的市場佔有率。我們始終專注於產品發布和地理擴張。
  • 2022 年 12 月，美國Guardant Health, Inc. 報告了 ECLIPSE 研究的正面結果。這項大規模研究包括 20,000 多名患者，旨在評估 Guardant Health 的血液檢測在中等風險成年人中檢測結直腸癌 (CRC) 的有效性。我當時就在場。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章 檢驗類型業務分析

  • 體外大腸直腸癌篩檢測試市場：測試類型變異分析
  • 大便潛血試驗
    • 2018-2030年大便潛血試驗市場
    • 瓜亞克 FOB糞便檢驗
    • 免疫FOB凝集試驗
    • 側流免疫FOB測試
    • 免疫 FOB ELISA 測試
  • 生物標記測試
    • 生物標記測試市場，2018-2030
    • 腫瘤M2-PK糞便檢驗
    • 轉鐵蛋白測定
    • 免疫 FOB ELISA 測試
  • CRC DNA 篩檢測試
    • 2018-2030年CRC DNA篩檢測試市場
    • 甲基化基因檢測
    • 小組 DNA 測試

第5章 區域業務分析

  • 體外大腸直腸癌篩檢測試市場佔有率：按地區分類，2022 年和 2030 年
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第6章 競爭形勢

  • 公司分類
  • 策略規劃
  • 2022 年公司市場佔有率分析
  • 公司簡介/名單
    • Abbott
    • Beckman Coulter Inc
    • Eiken Chemical Co., Ltd.
    • Epigenomics
    • Sysmex Corporation
    • Siemens Healthcare GmbH
    • Quest Diagnostics Incorporated
    • OncoCyte Corporation
    • Merck KGaA
    • Immunostics Inc.
    • Kyowa Kirin Co. Ltd.
    • Randox Laboratories Ltd.
    • R-Biopharm AG
Product Code: 978-1-68038-438-3

In-vitro Colorectal Cancer Screening Tests Market Growth & Trends:

The global in-vitro colorectal cancer screening tests market size is expected to reach USD 1.12 billion by 2030, expandingat a CAGR of 3.02% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising number of novel screening models to combat the increasing incidences of colon and rectal malignancy cases is the major factor influencing the market growth. The emergence of newly developed genetic and biomarker tests such as tumor M2-PK stool tests and methylated gene testing is anticipated to drive the adoption rate of tumor diagnostic models.

The increasing incidence of colorectal malignancy is a significant driver for the growth of the segment. For example, according to data released by the National Cancer Center Japan in June 2022, it was projected that there would be approximately 1,019,000 new cases of cancer in Japan in 2022, with Colorectal Cancer (CRC) accounting for an estimated 158,200 new cases. Similarly, data updated by Cancer Australia in August 2022 indicated that 15,713 new cases of CRC were expected to be diagnosed in Australia in 2022, with 8,300 cases among males and 7,413 cases among females. As a result, the increasing prevalence of colorectal malignance is anticipated to drive the demand for colonoscopy devices.

The implementation of various initiatives by public organizations to promote screening has positively impacted the demand for in-vitro CRC screenings. For instance, according to reports from Cancer.org, healthcare systems in California continued to provide FIT kits (fecal immunochemical tests) during the months of April and May 2020, and the response rates for FIT remained high despite the onset of the COVID-19 pandemic. Additionally, the European Cancer community has mobilized its resources to evaluate, address, and mitigate the adverse effects of COVID-19 on screening. These efforts have contributed to the sustained demand for in-vitro screening tests.

Furthermore, market growth is expected to be driven by the increasing number of product launches by major market players. These product launches are aimed at providing access to technologically advanced and innovative products. For instance, Pillar Biosciences, Inc. received FDA approval for the ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) in July 2021 for the detection of CRC.

In-vitro Colorectal Cancer Screening Tests Market Report Highlights:

  • Based on test type, fecal occult blood testing segment held the largest share of the market in 2022 due to their wider usage and easy applicability by large customer base
  • Among FOB test segment, immuno-FOB ELISA test held a significant share in 2022, as immunological testing offers more accuracy than conventional guaiac FOB stool test
  • Biomarker tests are expected to gain revenue share over the forecast period due to the emergence of noninvasive screening procedures
  • Tumor M2-PK stool test generated maximum revenue in 2022 due to recent product introduction such as ScheBo Tumor M2-PK Stool Test by ScheBo Biotech AG
  • In CRC DNA screening test vertical, panel DNA tests are gaining ground as these are advanced genetic screening tests, thus contributing the maximum revenue share
  • North America held the largest share of the market in 2022, which can be attributed to high adoption rate of these products in clinical workflow for detection of melanoma
  • Key players operating in the market include Abbott Laboratories; Quest Diagnostics; Siemens AG; Randox Laboratories; Kyowa Medex; and GeneNews and are constantly focusing on product launches and geographical expansion to gain higher share in the market
  • In December 2022, Guardant Health, Inc., a company based in the United States, reported positive findings from the ECLIPSE study. This extensive study involved more than 20,000 patients and aimed to assess the effectiveness of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test type segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing incidence of colon and rectal cancers
      • 3.2.1.2. Growing accuracy of colorectal cancer screening by use of genetic testing
      • 3.2.1.3. Presence of a number of colorectal cancer screening products in pipeline
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Pending investigational evidence for certain genetic screening tests
      • 3.2.2.2. Difficulty to undertake CRC screening tests to encompass the entire
      • 3.2.2.3. Lack of cancer screening guideless in Asia Pacific region
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Test Type Business Analysis

  • 4.1. In-vitro Colorectal Cancer Screening Tests Market: Test Type Movement Analysis
  • 4.2. Fecal Occult Blood Tests
    • 4.2.1. Fecal Occult Blood Tests Market, 2018 - 2030 (USD Million)
    • 4.2.2. Guaiac FOB Stool Test
      • 4.2.2.1. Guaiac FOB Stool Test Market, 2018 - 2030 (USD Million)
    • 4.2.3. Immuno-FOB Agglutination Test
      • 4.2.3.1. Immuno-FOB Agglutination Test Market, 2018 - 2030 (USD Million)
    • 4.2.4. Lateral Flow Immuno-FOB Test
      • 4.2.4.1. Lateral Flow Immuno-FOB Test Market, 2018 - 2030 (USD Million)
    • 4.2.5. Immuno-FOB ELISA Test
      • 4.2.5.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
  • 4.3. Biomarker Tests Market
    • 4.3.1. Biomarker Tests Market, 2018 - 2030 (USD Million)
    • 4.3.2. Tumor M2-PK Stool Test
      • 4.3.2.1. Tumor M2-PK Stool Test Market, 2018 - 2030 (USD Million)
    • 4.3.3. Transferrin Assays
      • 4.3.3.1. Transferrin Assays Market, 2018 - 2030 (USD Million)
    • 4.3.4. Immuno-FOB ELISA Test
      • 4.3.4.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
  • 4.4. CRC DNA Screening Tests
    • 4.4.1. CRC DNA Screening Tests Market, 2018 - 2030 (USD Million)
    • 4.4.2. Methylated Gene Testing
      • 4.4.2.1. Methylated Gene Testing Market, 2018 - 2030 (USD Million)
    • 4.4.3. Panel DNA Tests
      • 4.4.3.1. Panel DNA Tests Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. In-vitro Colorectal Cancer Screening Tests Market Share By Region, 2022 & 2030
  • 5.2. North America
    • 5.2.1. SWOT Analysis
    • 5.2.2. North America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.2.3. U.S.
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Target Disease Prevalence
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Regulatory Framework
      • 5.2.3.5. U.S. In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.2.4. Canada
      • 5.2.4.1. Key Country Dynamics
      • 5.2.4.2. Target Disease Prevalence
      • 5.2.4.3. Competitive Scenario
      • 5.2.4.4. Regulatory Framework
      • 5.2.4.5. Canada In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. SWOT Analysis
    • 5.3.2. Europe In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Target Disease Prevalence
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. Regulatory Framework
      • 5.3.3.5. UK In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.4. Germany
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Target Disease Prevalence
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. Regulatory Framework
      • 5.3.4.5. Germany In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.5. France
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Target Disease Prevalence
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Regulatory Framework
      • 5.3.5.5. France In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.6. Italy
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Target Disease Prevalence
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Regulatory Framework
      • 5.3.6.5. Italy In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.7. Spain
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Target Disease Prevalence
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Regulatory Framework
      • 5.3.7.5. Spain In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Target Disease Prevalence
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Regulatory Framework
      • 5.3.8.5. Sweden In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Target Disease Prevalence
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Regulatory Framework
      • 5.3.9.5. Norway In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.10. Denmark
      • 5.3.10.1. Key Country Dynamics
      • 5.3.10.2. Target Disease Prevalence
      • 5.3.10.3. Competitive Scenario
      • 5.3.10.4. Regulatory Framework
      • 5.3.10.5. Denmark In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.11. Russia
      • 5.3.11.1. Key Country Dynamics
      • 5.3.11.2. Target Disease Prevalence
      • 5.3.11.3. Competitive Scenario
      • 5.3.11.4. Regulatory Framework
      • 5.3.11.5. Russia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.12. Netherlands
      • 5.3.12.1. Key Country Dynamics
      • 5.3.12.2. Target Disease Prevalence
      • 5.3.12.3. Competitive Scenario
      • 5.3.12.4. Regulatory Framework
      • 5.3.12.5. Netherlands In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. SWOT Analysis
    • 5.4.2. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. Regulatory Framework
      • 5.4.3.5. Japan In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.4. China
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Target Disease Prevalence
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. Regulatory Framework
      • 5.4.4.5. China In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.5. India
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Target Disease Prevalence
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Regulatory Framework
      • 5.4.5.5. India In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Target Disease Prevalence
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Regulatory Framework
      • 5.4.6.5. Australia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.7. Thailand
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Target Disease Prevalence
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. Regulatory Framework
      • 5.4.7.5. Thailand In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.8. South Korea
      • 5.4.8.1. Key Country Dynamics
      • 5.4.8.2. Target Disease Prevalence
      • 5.4.8.3. Competitive Scenario
      • 5.4.8.4. Regulatory Framework
      • 5.4.8.5. South Korea In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. SWOT Analysis
    • 5.5.2. Latin America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.3. Brazil
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Target Disease Prevalence
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Regulatory Framework
      • 5.5.3.5. Brazil In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.4. Mexico
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Target Disease Prevalence
      • 5.5.4.3. Competitive Scenario
      • 5.5.4.4. Regulatory Framework
      • 5.5.4.5. Mexico In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.5. Argentina
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Target Disease Prevalence
      • 5.5.5.3. Competitive Scenario
      • 5.5.5.4. Regulatory Framework
      • 5.5.5.5. Argentina In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. SWOT Analysis
    • 5.6.2. MEA In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.3. South Africa
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Target Disease Prevalence
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Regulatory Framework
      • 5.6.3.5. South Africa In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.4. Saudi Arabia
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Target Disease Prevalence
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. Regulatory Framework
      • 5.6.4.5. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.5. UAE
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Target Disease Prevalence
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Regulatory Framework
      • 5.6.5.5. UAE In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.6. Kuwait
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Target Disease Prevalence
      • 5.6.6.3. Competitive Scenario
      • 5.6.6.4. Regulatory Framework
      • 5.6.6.5. Kuwait In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Market Share Analysis, 2022
  • 6.4. Company Profiles/Listing
    • 6.4.1. Abbott
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Beckman Coulter Inc
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Eiken Chemical Co., Ltd.
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Epigenomics
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. Sysmex Corporation
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Siemens Healthcare GmbH
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Quest Diagnostics Incorporated
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives
    • 6.4.8. OncoCyte Corporation
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Strategic Initiatives
    • 6.4.9. Merck KGaA
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Strategic Initiatives
    • 6.4.10. Immunostics Inc.
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Strategic Initiatives
    • 6.4.11. Kyowa Kirin Co. Ltd.
      • 6.4.11.1. Overview
      • 6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Strategic Initiatives
    • 6.4.12. Randox Laboratories Ltd.
      • 6.4.12.1. Overview
      • 6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.12.3. Product Benchmarking
      • 6.4.12.4. Strategic Initiatives
    • 6.4.13. R-Biopharm AG
      • 6.4.13.1. Overview
      • 6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.13.3. Product Benchmarking
      • 6.4.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global In-vitro Colorectal Cancer Screening Tests Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 5 North America In-vitro Colorectal Cancer Screening Tests Market, By Country, 2018 - 2030 (USD Million)
  • Table 6 North America In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 8 Canada America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 9 Europe America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 10 Europe America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 11 UK America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 12 Germany America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 13 France America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 14 Italy America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 15 Spain America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 16 Sweden America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 17 Norway America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 18 Russia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
  • Table 19 Denmark America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 20 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
  • Table 21 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 23 Japan America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 24 China America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 25 India America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 26 Australia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 27 Thailand America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 28 South Korea America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 29 Latin America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Latin America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 31 Brazil America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 32 Mexico America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 33 Argentina America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 34 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 35 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 36 South Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 37 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 38 UAE In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 39 UAE In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)
  • Table 40 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 In-vitro Colorectal Cancer Screening Tests Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 In-vitro colorectal cancer screening tests market: Test type outlook and key takeaways
  • Fig. 15 In-vitro colorectal cancer screening tests market: Test type movement analysis & market share 2022 & 2030
  • Fig. 16 Global fecal occult blood tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Global guaiac FOB stool tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Immuno-FOB agglutination tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lateral flow immuno-FOB tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Immuno-FOB ELISA tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Global biomarker tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Tumor M2-PK stool tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Transferrin assays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global CRC DNA screening tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Methylated gene testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Panel DNA tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Regional Marketplace: Key Takeaways
  • Fig. 28 Regional Outlook, 2022 & 2030
  • Fig. 29 Regional Market Dashboard
  • Fig. 30 Regional Market Place: Key Takeaways
  • Fig. 31 North America, SWOT Analysis
  • Fig. 32 Europe, SWOT Analysis
  • Fig. 33 Asia Pacific, SWOT Analysis
  • Fig. 34 Latin America, SWOT Analysis
  • Fig. 35 MEA, SWOT Analysis
  • Fig. 36 North America
  • Fig. 37 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Key Country Dynamics
  • Fig. 39 U.S. America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada Key Country Dynamics
  • Fig. 41 Canada America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 43 UK Key Country Dynamics
  • Fig. 44 UK America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany Key Country Dynamics
  • Fig. 46 Germany America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 47 France Key Country Dynamics
  • Fig. 48 France America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain Key Country Dynamics
  • Fig. 52 Spain America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden Key Country Dynamics
  • Fig. 54 Sweden America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 55 Norway Key Country Dynamics
  • Fig. 56 Norway America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark Key Country Dynamics
  • Fig. 58 Denmark America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 59 Russia Key Country Dynamics
  • Fig. 60 Russia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 61 Netherlands Key Country Dynamics
  • Fig. 62 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 64 Japan Key Country Dynamics
  • Fig. 65 Japan America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 66 China Key Country Dynamics
  • Fig. 67 China America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 68 India Key Country Dynamics
  • Fig. 69 India America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 70 Australia Key Country Dynamics
  • Fig. 71 Australia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand Key Country Dynamics
  • Fig. 73 Thailand America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea Key Country Dynamics
  • Fig. 75 South Korea America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil Key Country Dynamics
  • Fig. 78 Brazil America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico Key Country Dynamics
  • Fig. 80 Mexico America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina Key Country Dynamics
  • Fig. 82 Argentina America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa Key Country Dynamics
  • Fig. 85 South Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia Key Country Dynamics
  • Fig. 87 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 88 UAE Key Country Dynamics
  • Fig. 89 UAE America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait Key Country Dynamics
  • Fig. 91 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 92 Strategy Mapping